← The Wire·Earnings··2 outlets

Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more

The headline highlights several stocks making significant premarket moves, including Fiserv, Crinetics Pharmaceuticals, and Micron. This generic 'biggest movers' report often signals underlying catalysts for individual names, prompting a closer look at the drivers behind each stock's early trading activity.

The story

CNBC's premarket movers list points to several companies experiencing notable price action before the market open. While the headline itself is broad, it typically indicates that specific news or events are impacting these individual stocks, ranging from earnings reports to analyst upgrades/downgrades or company-specific announcements.

Crinetics Pharmaceuticals (CRNX) is one such name, showing a massive 640.7% year-over-year revenue growth, albeit from a small base of $7.7 million. However, this growth comes with significant unprofitability, evidenced by a -6046.0% net margin and a diluted EPS of -$4.95, indicating it is a high-growth, high-burn biotech.

Micron Technology (MU) is also on the list, reporting robust revenue of $37.4 billion, up 48.9% year-over-year, with healthy gross margins of 39.8% and net margins of 22.8%, translating to a diluted EPS of $7.59. Micron's performance is often a bellwether for the broader semiconductor memory market.

The premarket movements suggest that investors are reacting to specific news for each company. For CRNX, the focus would likely be on clinical trial data or funding rounds, given its early-stage financial profile. For MU, the movement could be tied to demand outlook for memory chips, particularly in AI and data center segments, or competitive dynamics.

Our read · Wed, Jul 8

Investors are weighing the premarket moves of Crinetics Pharmaceuticals (CRNX) and Micron (MU), assessing whether their underlying fundamentals justify the early price action.

Why. This is a pair trade capitalizing on the divergent risk/reward profiles of a high-growth, unprofitable biotech (CRNX) versus a profitable, cyclical semiconductor giant (MU). The premarket mention, while vague, indicates potential volatility that can be exploited by going long the more stable, profitable growth story and shorting the speculative play, particularly given CRNX's massive negative margins and EPS.

Both cases

The case it holdsMicron (MU) presents a strong bull case with robust revenue growth of 48.9% YoY and solid profitability (22.8% net margin, $7.59 diluted EPS), indicating a healthy position in the recovering semiconductor cycle.
The case it breaksCrinetics Pharmaceuticals (CRNX) faces a significant bear case due to its substantial unprofitability, with a staggering -6046.0% net margin and -$4.95 diluted EPS, despite high revenue growth, highlighting its cash burn and speculative nature.

What could change this view: A major positive clinical trial readout for CRNX or an unexpected downturn in chip demand for MU could unwind this trade. CRNX's high volatility means any positive news could trigger a significant short squeeze.

CRNX stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

CNBCWed, Jul 8 · 8:47 AM ETCNBC

Since this story · the companies named here, equal weight · +1.4%

Jul 8 · first close after publicationAug 31

Price context does not establish that the story caused the move.

Keep reading

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by CNBC, . Who answers for this

2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →